Dr Jewel Mullen Discusses NASEM's Framework for an Equitable Distribution of a COVID-19 Vaccine

Recently released vaccine data indicate encouraging steps forward in the global fight against coronavirus disease 2019 (COVID-19). When vaccine doses first become available, who should be prioritized?

Recently released vaccine data from Pfizer, Moderna, and AstraZeneca indicate encouraging steps forward in the global fight against coronavirus disease 2019 (COVID-19). But all 3 vaccines are still a long way from becoming readily available to the wider public, prompting the question, who should be prioritized once doses become available?

To provide guidance on this front, the National Institutes of Health (NIH) and CDC requested The National Academies of Science, Engineering, and Medicine (NASEM) to construct a framework assisting US policy makers and global health communities to plan for an equitable allocation of a COVID-19 vaccine.

On this episode of Managed Care Cast, we speak with Jewel Mullen, MD, MPH, the associate dean for health equity and associate professor of population health and internal medicine at the University of Texas at Austin, Dell Medical School. Mullen is the former principal deputy assistant secretary for health in HHS and a member of the National Academies committee which developed the framework for vaccine allocation.

Mullen discusses criteria used to prioritize vaccine recipients, barriers to equitable distribution, and the role of misinformation in the push for an effective COVID-19 vaccine.

Listen above or through one of these podcast services:

iTunes
TuneIn
Stitcher
Spotify

Read more:

Pfizer Says Vaccine 90% Effective; Biden Team Announces COVID-19 Transition Panel

Study Backs Decision to Move Forward With Pfizer Vaccine Candidate

Moderna SARS-CoV-2 Vaccine Elicits Response in Older Adults

Dr Maura Abbott: Talk to Your Patients About Their Vaccine Fears

Dr Maura Abbott: COVID-19 Vaccine Development Process Is Safe Despite a Quicker Timeline

Dr Victoria Smith on Experience Taking Part in a COVID-19 Vaccine Trial